ONO PHARMACEUTICAL CO.,LTD.

September 25, 2018

European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for Advanced BRAF-mutant Melanoma

This information is intended to notify the press release issued on September 20 (MT) by Array BioPharma Inc. Please click http://www.arraybiopharma.com/ for the original press release distributed by Array.

(1st paragraph of the press release)

Boulder, Colo. (September 20, 2018) – Array BioPharma Inc. (NASDAQ: ARRY) today announced that the European Commission (EC) has approved BRAFTOVI® in combination with MEKTOVI® for the treatment of adult patients with unresectable or metastatic melanoma with a $BRAF^{V600}$ mutation, as detected by a validated test. This approval is applicable to all 28 European Union (EU) member states, as well as Liechtenstein, Iceland and Norway.

About the Ono Pharmaceutical and Array BioPharma Collaboration

Ono Pharmaceutical Co., Ltd. ("ONO") entered into the license agreement with Array BioPharma Inc. regarding encorafenib, a BRAF inhibitor and binimetinib, a MEK inhibitor in May 2017 and received rights to develop and commercialize both products in Japan and South Korea.

In April 2018, ONO submitted applications for the manufacturing and marketing approval for both compounds in Japan for the indication of unresectable BRAF-mutant melanoma. Encorafenib and binimetinib are currently in two global Phase 3 clinical trials for the treatment of patients with BRAF-mutant melanoma (COLUMBUS study) and BRAF-mutant colorectal cancer (BEACON CRC study) as a combination therapy.

Contacts:
ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
public_relations@ono.co.jp